Novo Nordisk Levemir To Launch Within Next 12 Months
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-acting insulin analogue clears FDA June 17 for treatment of type 1 and type 2 diabetes. Firm says approval makes it the only company in U.S. with a "full range" of short-acting and long-acting insulin analogues.
You may also be interested in...
Novo Nordisk Declares Levemir A Winner In U.S. Market
Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.
Novo Nordisk Declares Levemir A Winner In U.S. Market
Sanofi-Aventis replacing Lilly as Novo's chief competitor in the diabetes market, company says.
Novo Nordisk Emphasizes Levemir “Predictability”
Planned second quarter launch would be nearly one year after FDA approval.